A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents

A Multicenter, Randomized, Controlled, Double Blinded Pivotal Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Adolescents Aged 12 Years to <18 Years

This was a prospective, randomized, double-blinded, multicenter, pivotal study evaluating the full dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The dose of VLA1553 or control was administered as single vaccination on Day 1. Overall, approximately 750 male and female participants aged 12 years to <18 years were enrolled into the study. After completion of the trial, a Post Trial Access program was performed to offer the VLA1553 vaccine to all placebo recipients.

This was a prospective, double-blinded, multicenter, randomized, pivotal Phase 3 study comprising 754 participants aged 12 years to <18 years randomized in a 2:1 ratio to the live-attenuated CHIKV vaccine candidate (VLA1553) or placebo. The dose of lyophilized VLA1553 or placebo was administered as a single intramuscular vaccination. Subjects in this study were stratified by baseline serostatus. The primary objective of the study was to evaluate the immunogenicity and safety of the full dose of VLA1553 28 days following the single vaccination. Immunogenicity evaluations in the immunogenicity subset included the proportion of subjects with neutralizing CHIKV antibody titers above the seroresponse threshold. The surrogate of protection reasonably likely to predict clinical benefit has been established in non-human primate passive transfer studies using human sera from the Phase 1 study. Safety data collection and immunogenicity were assessed until Month 12.

Inclusion Criteria:

1. male or female adolescents from the 12th birthday to the last day before the 18th birthday at the time of vaccination;

2. written informed consent by the subject's legal representative(s), and written informed assent of the subject;

3. generally healthy as determined by the Investigator's clinical judgement based on medical history, physical examination and screening laboratory tests;

4. seropositive for previous CHIKV exposure (i.e. IgM+/IgG+ or IgM-/IgG+) or seronegative (i.e. IgM-/IgG-) as screened by CHIKV-specific ELISA.

5. for women of childbearing potential:

   1. negative serum or urine pregnancy test at screening and on Day 1.
   2. practiced an adequate method of contraception during 30 days before screening
   3. agreed to employ adequate birth control measures for the first three months post-vaccination (i.e. until Day 85).

Exclusion Criteria:

1. Was taking medication or other treatment for unresolved symptoms attributed to a previous CHIKV infection; or had participated in a clinical study involving an investigational CHIKV vaccine;
2. acute or recent infection;
3. tested positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV);
4. live virus vaccine within 28 days or inactivated vaccine within 14 days prior to vaccination in this study or planned to receive a vaccine within 28 days or 14 days after vaccination, respectively;
5. abnormal findings in any required study investigations (including medical history, physical examination, and clinical laboratory) considered clinically relevant by the Investigator which pose a risk for participation in the study;
6. medical history of or currently had acute or progressive, unstable or uncontrolled clinical conditions that posed a risk for participation in the study;
7. history of immune-mediated or clinically relevant arthritis / arthralgia;
8. history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. If there had been surgical excision or treatment more than 5 years ago which was considered to have achieved a cure, the subject could be enrolled;
9. known or suspected defect of the immune system, such as subjects with congenital or acquired immunodeficiency, including infection with HIV, status post organ transplantation or immuno-suppressive therapy within 4 weeks prior to vaccination;
10. history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to components of the candidate vaccine, other known contraindications);
11. with clinical conditions representing a contraindication to intramuscular vaccination and blood draws;
12. pregnant or lactating at the time of enrollment;
13. received blood-derived products (e.g. plasma) within 90 days prior to vaccination in this study or planned to use blood products until Day 180 of the study;
14. rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating;
15. known or suspected problem with alcohol or drug abuse as determined by the Investigator;
16. any condition that, in the opinion of the Investigator, may compromise the subjects well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study;
17. committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities);
18. participation in another clinical study involving an investigational medicinal product (IMP) or device within 30 days prior to study enrollment or was scheduled to participate in another clinical study involving an IMP, or device during the course of this trial;
19. member of the team conducting the trial or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the trial.